Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1084P - Cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma (mCSCC): Preliminary safety and efficacy results from a phase I clinical trial

Date

17 Sep 2020

Session

E-Poster Display

Topics

Immunotherapy

Tumour Site

Basal Cell and Squamous Cell Cancers of the Skin

Presenters

Philip Clingan

Citation

Annals of Oncology (2020) 31 (suppl_4): S672-S710. 10.1016/annonc/annonc280

Authors

P. Clingan1, D. Brungs1, R. Ladwa2, A.M. Mant3, M. McGrath4, A. Tazbirkova5, P. Koralewski6, I. Lugowska7, C. Charoentum8, A. Dechaphunkul9, V. Sriuranpong10, J. Oliviero11, D.L. Harris12

Author affiliations

  • 1 Medical Oncology, Southern Medical Day Care Centre, 2500 - Wollongong/AU
  • 2 Medical Oncology, Princess Alexandra Hospital, 4102 - Brisbane/AU
  • 3 Medical Oncology, Eastern Health, 3128 - Melbourne/AU
  • 4 Medical Oncology, Gallipoli Medical Research Foundation, Greenslopes Private Hospital, 4120 - Greenslopes/AU
  • 5 Medical Oncology, Pindara Private Hospital, 4217 - Benowa/AU
  • 6 Medical Oncology, Szpital Specjalistyczny Ludwika Rydygiera, 31-826 - Krakow/PL
  • 7 Medical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 - Warsaw/PL
  • 8 Medical Oncology, Maharaj Nakorn Chiang Mai Hospital, 50200 - Chiang Mai/TH
  • 9 Medical Oncology, Prince of Songkla University, 90110 - Songkhla/TH
  • 10 Medical Oncology, King Chulalongkorn Memorial Hospital, 10330 - Bangkok/TH
  • 11 R&d, Checkpoint Therapeutics, 10014 - New York/US
  • 12 Medical Oncology, Christchurch Hospital, 8140 - Christchurch/NZ

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1084P

Background

Cosibelimab is a high affinity, fully-human IgG1 monoclonal antibody that directly binds to programmed death ligand-1 (PD-L1) and blocks its interaction with the programmed death receptor-1 (PD-1) and B7.1 receptors to restore an anti-tumor immune response. Cosibelimab has the additional benefit of a functional Fc domain capable of inducing antibody-dependent cellular cytotoxicity against tumor cells. Study CK-301-101 is a global, multicenter, multicohort trial that is enrolling patients (pts) with select advanced cancers, including a pivotal cohort of mCSCC (nodal and/or distant). Here we present preliminary safety data from the trial and efficacy data from the mCSCC cohort.

Methods

Eligible mCSCC pts (aged ≥18 years with histologically confirmed mCSCC and Eastern Cooperative Oncology Group performance status of 0-1) received a fixed dose of 800 mg cosibelimab administered intravenously every two weeks. The primary efficacy endpoint of objective response rate (ORR; complete response + partial response) by independent central review as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 is intended to provide the primary evidence of efficacy for product registration. The safety analysis includes all pts treated with at least one dose of cosibelimab.

Results

As of 17 April 2020, 103 pts have been treated, of which 92% experienced ≥1 treatment-emergent adverse event (AE), 36% experienced a grade ≥3 AE, and 6% experienced a grade ≥3 drug-related AE. The most common treatment-emergent AEs were fatigue (24%), anemia (22%), nausea and rash (17% each) and the most common drug-related AEs were rash (15%) and fatigue (13%). In 32 mCSCC pts evaluable for response, ORR based on investigator assessment of tumor response was 47%, including 3 complete responses and 12 partial responses. At the time of analysis, median duration of response was not reached, with 14/15 (93%) responses ongoing and 9 responses ≥6 months (longest, 14+).

Conclusions

Cosibelimab has a predictable and manageable safety profile and demonstrated robust clinical activity in mCSCC pts, including durable complete and partial responses. Enrollment is ongoing and updated results will be presented.

Clinical trial identification

NCT03212404.

Editorial acknowledgement

Legal entity responsible for the study

Checkpoint Therapeutics, Inc.

Funding

Checkpoint Therapeutics, Inc.

Disclosure

P. Clingan: Research grant/Funding (institution): Checkpoint Therapeutics, Inc.; Research grant/Funding (institution): Merck; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Eli Lilly; Research grant/Funding (institution): Bristol-Myers Squibb. D. Brungs, A.M. Mant, A. Tazbirkova, P. Koralewski: Research grant/Funding (institution): Checkpoint Therapeutics, Inc. R. Ladwa: Research grant/Funding (institution): Checkpoint Therapeutics, Inc.; Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: Merck; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ipsen; Advisory/Consultancy: Sanofi. M. McGrath: Research grant/Funding (institution): Checkpoint Therapeutics, Inc.; Advisory/Consultancy: Bristol Myers. I. Lugowska: Research grant/Funding (institution): Checkpoint Therapeutics, Inc.; Honoraria (self), Research grant/Funding (institution): Bristol-Myers Squibb; Honoraria (self): Merck; Honoraria (self), Research grant/Funding (institution): Roche; Honoraria (self): Amgen; Honoraria (self): Janssen; Honoraria (self), Research grant/Funding (institution): Novartis. C. Charoentum: Research grant/Funding (institution): Checkpoint Therapeutics, Inc.; Research grant/Funding (institution): Roche; Research grant/Funding (institution): AstraZeneca. A. Dechaphunkul: Research grant/Funding (institution): Checkpoint Therapeutics, Inc.; Travel/Accommodation/Expenses: Eisai. V. Sriuranpong: Research grant/Funding (institution): Checkpoint Therapeutics, Inc.; Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): Novartis; Honoraria (self), Research grant/Funding (institution): Roche; Honoraria (self), Research grant/Funding (institution): Pfizer; Honoraria (self): Sanofi; Honoraria (self), Research grant/Funding (institution): Eisai; Honoraria (self), Research grant/Funding (institution): Boehringer; Honoraria (self), Research grant/Funding (institution): Taiho; Honoraria (self), Research grant/Funding (institution): Merck; Honoraria (self): Bristol Myers; Advisory/Consultancy: Amgen. J. Oliviero: Shareholder/Stockholder/Stock options, Full/Part-time employment, Officer/Board of Directors: Checkpoint Therapeutics, Inc. D.L. Harris: Research grant/Funding (institution): Checkpoint Therapeutics, Inc.; Research grant/Funding (institution): Merck; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Targovax.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.